The Oncologist, Vol. 6, No. 1, 34-55,
February 2001
© 2001 AlphaMed Press
Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities
Eric Jonasch,
Frank G. Haluska
Massachusetts General Hospital, Boston, Massachusetts, USA
Correspondence:
Eric Jonasch, M.D., Cox 640, Division of Hematology-Oncology, 55 Fruit Street, Boston, Massachusetts 02114, USA. Telephone: 617-724-6582; Fax: 617-726-6974; e-mail: Ejonasch{at}partners.org
For the past 40 years, various forms of interferon (IFN) have been evaluated as therapy in a number of malignant and non-malignant diseases. With the advent of gene cloning, large quantities of pure IFN became available for clinical study. This paper reviews the biology, pharmacology, and clinical applications of IFN formulations most commonly used in oncology. It then reviews the most common side effects seen in patients treated with IFN, and makes recommendations for the management of IFN-induced toxicity.
The major oncological indications for IFN include melanoma, renal cell carcinoma, AIDS-related Kaposi's sarcoma, follicular lymphoma, hairy cell leukemia, and chronic myelogenous leukemia. Unfortunately, IFN therapy is associated with significant toxicity, which can be divided into constitutional, neuropsychiatric, hematologic, and hepatic effects. These toxicities have a major impact on the patient's quality of life, and on the physician's ability to optimally treat the patient. Careful attention to all aspects of patient care can result in improved tolerability of this difficult but promising therapy. Conclusion: a better understanding of IFN biology, indications, side effect profiles, and toxicity management will aid in optimizing its use in the treatment of patients with cancer.
Key Words. Interferon • Cancer • Clinical applications • Toxicity • Management
This article has been cited by other articles:

|
 |

|
 |
 
J. F. Mushinski, P. Nguyen, L. M. Stevens, C. Khanna, S. Lee, E. J. Chung, M.-J. Lee, Y. S. Kim, W. M. Linehan, M. A. Horisberger, et al.
Inhibition of Tumor Cell Motility by the Interferon-inducible GTPase MxA
J. Biol. Chem.,
May 29, 2009;
284(22):
15206 - 15214.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Biswas, J. Kelly, and T. Eisen
Cytoreductive Nephrectomy in Metastatic Clear-Cell Renal Cell Carcinoma: Perspectives in the Tyrosine Kinase Inhibitor Era
Oncologist,
January 1, 2009;
14(1):
52 - 59.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Dal Lago, V. D'Hondt, and A. Awada
Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors
Oncologist,
August 1, 2008;
13(8):
845 - 858.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. van Leeuwen, M. Pedersen, P. J.M. Hendriksen, A. Boorsma, M. H.M. van Herwijnen, R. W.H. Gottschalk, M. Kirsch-Volders, L. E. Knudsen, R. J. Sram, E. Bajak, et al.
Genomic analysis suggests higher susceptibility of children to air pollution
Carcinogenesis,
May 1, 2008;
29(5):
977 - 983.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Lechner, N. Malloth, T. Seppi, B. Beer, P. Jennings, and W. Pfaller
IFN-{alpha} induces barrier destabilization and apoptosis in renal proximal tubular epithelium
Am J Physiol Cell Physiol,
January 1, 2008;
294(1):
C153 - C160.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Morikawa, A. Sugiyama, H. Kume, S. Ota, T. Kashima, K. Tomita, T. Kitamura, T. Kodama, M. Fukayama, and H. Aburatani
Identification of Toll-Like Receptor 3 as a Potential Therapeutic Target in Clear Cell Renal Cell Carcinoma
Clin. Cancer Res.,
October 1, 2007;
13(19):
5703 - 5709.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. W. Ryan, B. H. Goldman, P. N. Lara Jr, P. C. Mack, T. M. Beer, C. M. Tangen, D. Lemmon, C.-X. Pan, H. A. Drabkin, and E. D. Crawford
Sorafenib With Interferon Alfa-2b As First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology Group
J. Clin. Oncol.,
August 1, 2007;
25(22):
3296 - 3301.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Ramos, P. Ruiz Jr, L. Ratner, I. M. Reis, C. Brites, C. Pedroso, G. E. Byrne Jr, N. L. Toomey, V. Andela, E. W. Harhaj, et al.
IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma
Blood,
April 1, 2007;
109(7):
3060 - 3068.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Parton, M. Gore, and T. Eisen
Role of Cytokine Therapy in 2006 and Beyond for Metastatic Renal Cell Cancer
J. Clin. Oncol.,
December 10, 2006;
24(35):
5584 - 5592.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Hohle, A. Karger, P. Konig, K. Giesow, and G. M. Keil
High-level expression of biologically active bovine alpha interferon by Bovine herpesvirus 1 interferes only marginally with recombinant virus replication in vitro
J. Gen. Virol.,
October 1, 2005;
86(10):
2685 - 2695.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Caraccio, A. Dardano, F. Manfredonia, L. Manca, L. Pasquali, A. Iudice, L. Murri, E. Ferrannini, and F. Monzani
Long-Term Follow-Up of 106 Multiple Sclerosis Patients Undergoing Interferon-{beta} 1a or 1b Therapy: Predictive Factors of Thyroid Disease Development and Duration
J. Clin. Endocrinol. Metab.,
July 1, 2005;
90(7):
4133 - 4137.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Caraccio, R. Giannini, S. Cuccato, P. Faviana, P. Berti, D. Galleri, A. Dardano, F. Basolo, E. Ferrannini, and F. Monzani
Type I Interferons Modulate the Expression of Thyroid Peroxidase, Sodium/Iodide Symporter, and Thyroglobulin Genes in Primary Human Thyrocyte Cultures
J. Clin. Endocrinol. Metab.,
February 1, 2005;
90(2):
1156 - 1162.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Pitha-Rowe, W. J. Petty, Q. Feng, P. H. Koza-Taylor, D. A. DiMattia, L. Pinder, K. H. Dragnev, N. Memoli, V. Memoli, T. Turi, et al.
Microarray Analyses Uncover UBE1L as a Candidate Target Gene for Lung Cancer Chemoprevention
Cancer Res.,
November 1, 2004;
64(21):
8109 - 8115.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Schroder, P. J. Hertzog, T. Ravasi, and D. A. Hume
Interferon-{gamma}: an overview of signals, mechanisms and functions
J. Leukoc. Biol.,
February 1, 2004;
75(2):
163 - 189.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Hartmann, B. Wollenberg, S. Rothenfusser, M. Wagner, D. Wellisch, B. Mack, T. Giese, O. Gires, S. Endres, and G. Hartmann
Identification and Functional Analysis of Tumor-Infiltrating Plasmacytoid Dendritic Cells in Head and Neck Cancer
Cancer Res.,
October 1, 2003;
63(19):
6478 - 6487.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. von Marschall, A. Scholz, T. Cramer, G. Schafer, M. Schirner, K. Oberg, B. Wiedenmann, M. Hocker, and S. Rosewicz
Effects of Interferon Alpha on Vascular Endothelial Growth Factor Gene Transcription and Tumor Angiogenesis
J Natl Cancer Inst,
March 19, 2003;
95(6):
437 - 448.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. F. Kefford
Adjuvant therapy of cutaneous melanoma: the interferon debate
Ann. Onc.,
March 1, 2003;
14(3):
358 - 365.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Yang, M. S. Merchant, M. E. Romero, M. Tsokos, L. H. Wexler, U. Kontny, C. L. Mackall, and C. J. Thiele
Induction of Caspase 8 by Interferon {gamma} Renders Some Neuroblastoma (NB) Cells Sensitive to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) but Reveals That a Lack of Membrane TR1/TR2 Also Contributes to TRAIL Resistance in NB
Cancer Res.,
March 1, 2003;
63(5):
1122 - 1129.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Nakanishi, Y. Mizutani, A. Kawauchi, O. Ukimura, T. Shiraishi, M. Hatano, M. Mizuno, J. Yoshida, and T. Miki
Significant Antitumoral Activity of Cationic Multilamellar Liposomes Containing Human IFN-{beta} Gene against Human Renal Cell Carcinoma
Clin. Cancer Res.,
March 1, 2003;
9(3):
1129 - 1135.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. M. Antoniou, E. Ferdoutsis, and D. Bouros
Interferons and Their Application in the Diseases of the Lung
Chest,
January 1, 2003;
123(1):
209 - 216.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Duguay, F. Mercier, J. Stagg, D. Martineau, J. Bramson, M. Servant, R. Lin, J. Galipeau, and J. Hiscott
In Vivo Interferon Regulatory Factor 3 Tumor Suppressor Activity in B16 Melanoma Tumors
Cancer Res.,
September 15, 2002;
62(18):
5148 - 5152.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. B. Lens and M. Dawes
Interferon Alfa Therapy for Malignant Melanoma: A Systematic Review of Randomized Controlled Trials
J. Clin. Oncol.,
April 1, 2002;
20(7):
1818 - 1825.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by AlphaMed Press.
|
|